[1] Stupp R,Mason WP,van den Bent MJ,et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma[J].N Engl J Med,2005,352(10):987-996.

[2] Stupp R,Hegi ME,Mason WP,et al.Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study:5-year analysis of the EORTC-NCIC trial[J].Lancet Oncol,2009,10(5):459-466.

[3] Wong ET,Hess KR,Gleason MJ,et al.Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase Ⅱ clinical trials[J].J Clin Oncol,1999,17(8):2572-2578.

[4] Hicklin DJ,Ellis LM.Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis[J].J Clin Oncol,2005,23(5):1011-1027.

[5] Miletic H,Niclou SP,Johansson M,et al.Anti-VEGF therapies for malignant glioma:treatment effects and escape mechanisms[J].Expert Opin Ther Targets,2009,13(4):455-468.

[6] Ferrara N,Gerber HP,LeCouter J.The biology of VEGF and its receptors[J].Nat Med,2003,9(6):669-676.

[7] Specenier P.Bevacizumab in glioblastoma multiforme[J].Expert Rev Anticancer Ther,2012,12(1):9-18.

[8] Stark-Vance V.Bevacizumab and CPT-11 in the treatment of relapsed malignant glioma [abstract] [J].Neurol Oncol,2005,7:369.

[9] Vredenburgh JJ,Desjardins A,Herndon JE,et al.Phase Ⅱ trial of bevacizumab and irinotecan in recurrent malignant glioma[J].Clin Cancer Res,2007,13(4):1253-1259.

[10] Vredenburgh JJ,Desjardins A,Herndon JE,et al.Bevacizumab plus irinotecan in recurrent glioblastoma multiforme[J].J Clin Oncol,2007,25(30):4722-4729.

[11] Friedman HS,Prados MD,Wen PY,et al.Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma[J].J Clin Oncol,2009,27(28):4733-4740.

[12] Cloughesy T,Day B,Das A,et al.Updated safety and survival of patients with relapsed glioblastoma treated with bevacizumab in the BRAIN study[J].J Clin Oncol,2010,28(15 Suppl):181s.

[13] Kreisl TN,Kim L,Moore K,et al.Phase Ⅱ trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma[J].J Clin Oncol,2009,27(5):740-745.

[14] Taal W,Oosterkamp HM,Walenkamp AME,et al.Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial):a randomised controlled phase 2 trial[J].Lancet Oncol,2014,15(9):943-953.

[15] Khasraw M,Ameratunga M,Grommes C.Bevacizumab for the treatment of high-grade glioma:an update after phase Ⅲ trials[J].Expert Opin Biol Ther,2014,14(5):729-740.

[16] Raizer JJ,Grimm S,Chamberlain MC,et al.A phase 2 trial of single-agent bevacizumab given in an every-3-week schedule for patients with recurrent high-grade gliomas[J].Cancer,2010,116(22):5297-5305.

[17] Kreisl TN,Zhang W,Odia Y,et al.A phase Ⅱ trial of single-agent bevacizumab in patients with recurrent anaplastic glioma[J].Neurol Oncol,2011,13(10):1143-1150.

[18] Nagane M,Nishikawa R,Narita Y,et al.Phase Ⅱ study of single-agent bevacizumab in Japanese patients with recurrent malignant glioma[J].Jap J Clin Oncol,2012,42(10):887-895.

[19] Hofer S,Elandt K,Greil R,et al.Clinical outcome with bevacizumab in patients with recurrent high-grade glioma treated outside clinical trials[J].Acta Oncologica,2011,50(5):630-635.

[20] Zhang G,Huang S,Wang Z.A meta-analysis of bevacizumab alone and in combination with irinotecan in the treatment of patients with recurrent glioblastoma multiforme[J].J Clin Neurosci,2012,19(12):1636-1640.

[21] Balana C,Etxaniz O,Buges C,et al.Approval denied by the European Medicines Agency (EMA) for bevacizumab in the treatment of high-grade glioma recurrence:A good idea or a grave error? [J].Clin Translat Oncol,2011,13(3):209-210.

[22] Gil MJ,Mesia C,Rey M,et al.Bevacizumab for the treatment of glioblastoma[J].Clin Med Insights Oncol,2013,7:123-135.

[23] Lai A,Tran A,Nghiemphu PL,et al.Phase Ⅱ study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme[J].J Clin Oncol,2011,29(2):142-148.

[24] Gilbert MR,Dignam JJ,Armstrong TS,et al.A randomized trial of bevacizumab for newly diagnosed glioblastoma[J].N Engl J Med,2014,370(8):699-708.

[25] Chinot OL,Wick W,Mason W,et al.Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma[J].N Engl J Med,2014,370(8):709-722.

[26] Chauffert B,Feuvret L,Bonnetain F,et al.Randomized phase Ⅱ trial of irinotecan and bevacizumab as neo-adjuvant and adjuvant to temozolomide-based chemoradiation compared with temozolomide-chemoradiation for unresectable glioblastoma:final results of the TEMAVIR study from ANOCEFdagger[J].Ann Oncol,2014,25(7):1442-1447.

[27] Khasraw M,Lassman AB,Ashley DM,et al.A meta-analysis of antiangiogenic therapy for glioblastoma (GBM) [J].J Clin Oncol,2014,32(15 Suppl).

[28] Magnuson W,Ian Robins H,Mohindra P,et al Large volume reirradiation as salvage therapy for glioblastoma after progression on bevacizumab[J].J Neurooncol,2014,117(1):133-139.

[29] Carbonell WS,DeLay M,Jahangiri A,et al.β1 integrin targeting potentiates antiangiogenic therapy and inhibits the growth of bevacizumab-resistant glioblastoma[J].Cancer Res,2013,73(10):3145-3154.

[30] Soda Y,Myskiw C,Rommel A,et al.Mechanisms of neovascularization and resistance to anti-angiogenic therapies in glioblastoma multiforme[J].J Mol Med (Berl),2013,91(4):439-448.

[31] Piao Y,Liang J,Holmes L,et al.Acquired resistance to anti-VEGF therapy in glioblastoma is associated with a mesenchymal transition[J].Clin Cancer Res,2013,19(16):4392-4403.

[32] Chamberlain MC,Johnston SK.Salvage therapy with single agent bendamustine for recurrent glioblastoma[J].J Neurol Oncol,2011,105(3):523-530.

[33] Norden AD,Young GS,Setayesh K,et al.Bevacizumab for recurrent malignant gliomas:efficacy,toxicity,and patterns of recurrence[J].Neurology,2008,70(10):779-787.

[34] Gilbert MR,Aldape K.RTOG 0625:a phase Ⅱ study of bevacizumab with irinotecan in recurrent glioblastoma (GBM) [J].J Clin Oncol,2009,27(Suppl 15):89s.

[35] Gil MJ,De Las Penas R,Reynes G,et al.Bevacizumab plus irinotecan in recurrent malignant glioma shows high overall survival in a multicenter retrospective pooled series of the Spanish Neuro-Oncology Research Group (GEINO) [J].Anti Cancer Drugs,2012,23(6):659-665.

[36] Zuniga RM,Torcuator R,Jain R,et al.Efficacy,safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan[J].J Neurol Oncol,2009,91(3):329-336.

[37] Lombardi G,Zustovich F,Farina P,et al.Hypertension as a biomarker in patients with recurrent glioblastoma treated with antiangiogenic drugs:a single-center experience and a critical review of the literature[J].Anticancer Drugs,2013,24(1):90-97.